Pereira L M, Langley P G, Hayllar K M, Tredger J M, Williams R
Institute of Liver Studies, King's College Hospital, Denmark Hill, London.
Gut. 1992 Jan;33(1):98-102. doi: 10.1136/gut.33.1.98.
The value of coagulation factor V and VIII/V levels as prognostic indicators was assessed in 27 patients with fulminant hepatic failure and compared with other predictive indices. Admission factor V levels were significantly reduced in 22 patients with paracetamol induced hepatic failure compared with a healthy control group (median 9.5% v 103%, respectively; p less than 0.001) and with lower values in non-A non-B hepatitis (median 2.7%). Values in the seven patients who died after paracetamol overdose, considered together with the four who underwent liver transplantation (group median 5.1%), were significantly lower than in the 11 who survived (median 11.8%; p less than 0.01). Median admission factor VIII was higher in those who died or received a transplant than in those who survived (298% v 162%; p less than 0.05), with both results higher than in healthy volunteers (median 104%; p less than 0.01) but lower than in non-A non-B hepatitis (median 340%). The ratio of factor VIII/V on admission was less than 30 in all patients who survived paracetamol overdose (median 17) with corresponding values greater than 30 in 10 of 11 of those who died (median 39). A factor V result less than or equal to 10% on admission predicted an adverse outcome in 10 of 11 fatal cases, a 91% sensitivity which was greater than for the previously defined indicator of an arterial blood pH less than 7.30 on admission (sensitivity 82%). Prothrombin time at admission or on day 4 did not usefully predict outcome in our series. Predictive accuracy was 73% and 82% for factor V and admission acidosis respectively and 95% for factor V in conjunction with admission coma grade III or IV and factor VIII (ratio > 30). These criteria may be useful in selecting patients with paracetamol induced fulminant hepatic failure for transplantation.
对27例暴发性肝衰竭患者评估了凝血因子V及VIII/V水平作为预后指标的价值,并与其他预测指标进行了比较。与健康对照组相比,22例对乙酰氨基酚所致肝衰竭患者入院时的因子V水平显著降低(中位数分别为9.5%和103%;p<0.001),在非甲非乙型肝炎患者中更低(中位数为2.7%)。对乙酰氨基酚过量后死亡的7例患者以及接受肝移植的4例患者(组中位数为5.1%)的因子V水平显著低于存活的11例患者(中位数为11.8%;p<0.01)。死亡或接受移植患者的入院因子VIII中位数高于存活患者(298%对162%;p<0.05),两者结果均高于健康志愿者(中位数为104%;p<0.01),但低于非甲非乙型肝炎患者(中位数为340%)。对乙酰氨基酚过量存活的所有患者入院时因子VIII/V比值均小于30(中位数为17),而死亡的11例患者中有10例相应值大于30(中位数为39)。入院时因子V结果小于或等于10%可预测11例致命病例中的10例不良结局,敏感度为91%,高于入院时动脉血pH小于7.30这一先前定义的指标(敏感度为82%)。在我们的研究系列中,入院时或第4天的凝血酶原时间对结局的预测并无帮助。因子V和入院酸中毒的预测准确率分别为73%和82%,因子V联合入院时III级或IV级昏迷及因子VIII(比值>30)的预测准确率为95%。这些标准可能有助于选择对乙酰氨基酚所致暴发性肝衰竭患者进行移植。